Oaxaca de Juárez, 4 November. Hepatitis C is a life-threatening liver disease, because if it is not treated at the right time, it can cause liver cirrhosis, kidney failure and, in some cases, liver cancer, warns Dr. Margarita Dehesa, a specialist in gastroenterology.
He also said that in advanced cases, the disease may even require liver transplantation, so a diagnosis is necessary because currently it is estimated that there are between 400,000 and 600,000 Mexicans infected with this virus, most of whom do not know.
"We can not deny that the therapeutic approach to the disease has been significantly transformed, but there are still great challenges when it comes to care and diagnosis in time, because 80 percent of people living with the virus are not aware of their infection status and only 20 percent are diagnosed." He said.
Therefore, he added that screening should be encouraged and a plan should be devised to eliminate disease with government participation, private initiative, civil society and academia.
This was announced in the context of the presentation of the treatment of hepatitis C, in which it was found that it is an oral single intake and without ribavirin treatment for adults with chronic hepatitis virus infection. C in all major genotypes – from 1 to 6, which is already available in Mexico.
For her part, Dr. Rosalba Moreno, head of the Gastroenterological Special Service Hospital at the National Medical Center of the 21st Century Mexican Institute of Social Security (IMSS) explained that "this new therapy, which in the vast majority of cases has a period of 8 weeks is indicated for patients without cirrhosis liver, regardless of whether patients have not previously received treatment or who have already received other previous treatment, so it can be used in most Mexican patients living with the virus .Virictive hepatitis C, which is an advantage for both patients and doctors . "
Gastroenterology and endoscopy of the gastrointestinal tract added that the therapy will also benefit patients with specific therapeutic challenges, including patients with compensated cirrhosis, in all major genotypes, as well as patients who previously had limited treatment options, e.g. with severe chronic kidney disease (CKD) or chronic hepatitis C virus genotype 3 infection.